Advances in sepsis biomarkers.

Area of Science:

• Infectious Diseases
• Immunology
• Clinical Diagnostics

Background:

• Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
• It is a major global health challenge, leading to high morbidity and mortality in hospitalized patients.
• Accurate and timely diagnosis is crucial for effective management.

Purpose of the Study:

• To provide a comprehensive review of sepsis, from basic principles to advanced diagnostics.
• To discuss established and novel biomarkers for sepsis detection and monitoring.
• To highlight future directions in sepsis biomarker research and clinical application.

Main Methods:

• Literature review of infectious diseases, sepsis pathophysiology, and definitions.
• Analysis of established sepsis biomarkers (lactate, procalcitonin, C-reactive protein).
• Evaluation of novel biomarkers including white blood cell assays and immune response molecules.
• Exploration of emerging biomarkers and panels for future sepsis management.

Main Results:

• Established biomarkers like procalcitonin offer valuable insights into sepsis diagnosis.
• Novel biomarkers, including those assessing white blood cell function, show promise for earlier detection.
• Emerging biomarker panels may offer a more comprehensive approach to sepsis management.
• The review synthesizes current knowledge and identifies gaps in sepsis diagnostics.

Conclusions:

• Understanding sepsis pathophysiology and definitions is fundamental.
• A range of biomarkers, from established to novel, aids in sepsis diagnosis and management.
• Continued research into emerging biomarkers and panels is essential for advancing sepsis care.
• Optimizing biomarker use can improve patient outcomes and reduce mortality.